Primate Monocytes - CD14, CD16 - Ziegler-Heitbrock


Montmorency Cherry Juice Consumption does not Improve Muscle Soreness or Inhibit Pro-inflammatory Monocyte Responses Following an Acute Bout of Whole-body Resistance Training.


Montmorency Cherry Juice (MCJ) may improve acute exercise recovery by attenuating inflammation and oxidative stress. However, the anti-inflammatory effects of MCJ on monocyte responses following resistance exercise have not been explored. Seven resistance-trained males (age: 22.9 +- 4.1 yrs; height: 1.8 +- 0.1 m; weight: 81.7 +- 13.2 kg) participated in this study. Participants completed a placebo-controlled crossover design, drinking either MCJ or placebo beverages, 7 days prior to completing an acute bout of unilateral resistance exercise. Statistical significance was assessed using a withinsubjects repeated measures ANOVA; alpha level p <= 0.05. Main effects for time were observed for changes in classical and intermediate monocytes (p <= 0.05), but no significant treatment effects were observed for monocyte subtypes p > 0.05. Classical monocytes (CD14+ CD16-) increased and peaked 24 hr post-exercise (placebo 1.14 +- 0.04 and MCJ 1.06 +- 0.06-fold). Intermediate monocytes peaked 48 hr post-exercise increasing 1.82 +- 0.41 and 2.01 +- 0.80- fold. Nonclassical monocytes peaked post-exercise (placebo 1.17 +- 0.31 and MCJ 1.02 +- 0.20-fold). Peak pain visual analog scale (VAS) occurred post-exercise for MCJ (3.63 +- 2.01-fold) and 72 hr post-exercise for placebo (4.26 +- 3.46- fold). IL-6 and pressure pain threshold (PPT) peaked 24 hr post-exercise (IL-6 placebo 3.83 +- 1.01- and MCJ 6.43 +- 3.43-fold) and (PPT placebo 86.37 +- 3.95% and MCJ 82.81 +- 2.90% of pressure needed at pre-exercise). Our data suggests MCJ consumption does not decrease muscle soreness, IL-6, or monocyte subset responses following a high-intensity resistance exercise protocol in resistance-trained males.

Authors: Drummer DJ, Many GM, Pritchett K, Young M, Connor KR, Tesfaye J, Dondji B, Pritchett RC,
Journal: Int J Exerc Sci;2022; 15 (6) 686-701
Year: 2022
PubMed: PMID: 35991938 (Go to PubMed)